Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aref Al-Kali

Showing results (41-50 of 148) with videos related to

Pageof 15
Sort By:
Blood Cancer Journal|January 18, 2024
One thousand patients with essential thrombocythemia: the Mayo Clinic experienceNaseema Gangat, Omer Karrar, Aref Al-Kali, et al.
British Journal of Haematology|September 15, 2023
Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patientsAhmad Nanaa, Rong He, James M Foran, et al.
Annals of Hematology|July 18, 2020
Favorable outcomes of acute leukemias of ambiguous lineage treated with hyperCVAD: a multi-center retrospective studyVu H Duong, Kebede H Begna, Sarah Kashanian, et al.
Mayo Clinic Proceedings|January 4, 2012
One thousand patients with primary myelofibrosis: the mayo clinic experienceAyalew Tefferi, Terra L Lasho, Thitina Jimma, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 28, 2017
Inversion 3 Cytogenetic Abnormality in an Allogeneic Hematopoietic Cell Transplant Recipient Representative of a Donor-Derived Constitutional AbnormalityAjoy Dias, Aref Al-Kali, Daniel Van Dyke, et al.
Journal of Hematology & Oncology|October 21, 2015
The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemiaRaoul Tibes, Aref Al-Kali, Gavin R Oliver, et al.
Oncotarget|December 8, 2017
Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of acute myeloid leukemia cells from cytarabineRosalie M Sterner, Kimberly N Kremer, Aref Al-Kali, et al.
American Journal of Hematology|February 14, 2022
Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive casesAmritpal Singh, Aref Al-Kali, Kebede H Begna, et al.
Blood Cancer Journal|March 9, 2018
Momelotinib therapy for myelofibrosis: a 7-year follow-upAyalew Tefferi, Daniela Barraco, Terra L Lasho, et al.
Annals of Hematology|October 19, 2018
Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapyOmar A Alkharabsheh, Salwa S Saadeh, Darci L Zblewski, et al.
Pageof 15

Showing results (41-50 of 148) with videos related to

Sort By:
Pageof 15
Blood Cancer Journal|January 18, 2024
One thousand patients with essential thrombocythemia: the Mayo Clinic experienceNaseema Gangat, Omer Karrar, Aref Al-Kali, et al.
British Journal of Haematology|September 15, 2023
Venetoclax plus hypomethylating agents in DDX41-mutated acute myeloid leukaemia and myelodysplastic syndrome: Mayo Clinic series on 12 patientsAhmad Nanaa, Rong He, James M Foran, et al.
Annals of Hematology|July 18, 2020
Favorable outcomes of acute leukemias of ambiguous lineage treated with hyperCVAD: a multi-center retrospective studyVu H Duong, Kebede H Begna, Sarah Kashanian, et al.
Mayo Clinic Proceedings|January 4, 2012
One thousand patients with primary myelofibrosis: the mayo clinic experienceAyalew Tefferi, Terra L Lasho, Thitina Jimma, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 28, 2017
Inversion 3 Cytogenetic Abnormality in an Allogeneic Hematopoietic Cell Transplant Recipient Representative of a Donor-Derived Constitutional AbnormalityAjoy Dias, Aref Al-Kali, Daniel Van Dyke, et al.
Journal of Hematology & Oncology|October 21, 2015
The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemiaRaoul Tibes, Aref Al-Kali, Gavin R Oliver, et al.
Oncotarget|December 8, 2017
Histone deacetylase inhibitors reduce differentiating osteoblast-mediated protection of acute myeloid leukemia cells from cytarabineRosalie M Sterner, Kimberly N Kremer, Aref Al-Kali, et al.
American Journal of Hematology|February 14, 2022
Midostaurin therapy for advanced systemic mastocytosis: Mayo Clinic experience in 33 consecutive casesAmritpal Singh, Aref Al-Kali, Kebede H Begna, et al.
Blood Cancer Journal|March 9, 2018
Momelotinib therapy for myelofibrosis: a 7-year follow-upAyalew Tefferi, Daniela Barraco, Terra L Lasho, et al.
Annals of Hematology|October 19, 2018
Frequency of venous thrombotic events in patients with myelodysplastic syndrome and 5q deletion syndrome during lenalidomide therapyOmar A Alkharabsheh, Salwa S Saadeh, Darci L Zblewski, et al.
Pageof 15